[go: up one dir, main page]

WO2008015563A3 - Salts of rosuvastatin and processes for their preparation - Google Patents

Salts of rosuvastatin and processes for their preparation Download PDF

Info

Publication number
WO2008015563A3
WO2008015563A3 PCT/IB2007/002242 IB2007002242W WO2008015563A3 WO 2008015563 A3 WO2008015563 A3 WO 2008015563A3 IB 2007002242 W IB2007002242 W IB 2007002242W WO 2008015563 A3 WO2008015563 A3 WO 2008015563A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
salts
salt
processes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002242
Other languages
French (fr)
Other versions
WO2008015563A2 (en
Inventor
Narendra Shriram Joshi
Anil Shahaji Khile
Yogesh Baburao Kajale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Pharmaceuticals Ltd
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Priority to EP07804703A priority Critical patent/EP2066644A2/en
Publication of WO2008015563A2 publication Critical patent/WO2008015563A2/en
Publication of WO2008015563A3 publication Critical patent/WO2008015563A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel salts of rosuvastatin and processes for their preparation are disclosed. Pharmaceutical compositions comprising a therapeutically effective amount of one or more salts of rosuvastatin selected from the group consisting of a barium salt, strontium salt, zinc salt, cesium salt, cadmium salt and mixtures thereof are also disclosed.
PCT/IB2007/002242 2006-08-04 2007-08-03 Salts of rosuvastatin and processes for their preparation Ceased WO2008015563A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07804703A EP2066644A2 (en) 2006-08-04 2007-08-03 Salts of rosuvastatin and processes for their preparation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1245/MUM/2006 2006-08-04
IN1245MU2006 2006-08-04
IN1267/MUM/2006 2006-08-10
IN1268MU2006 2006-08-10
IN1268/MUM/2006 2006-08-10
IN1267MU2006 2006-08-10

Publications (2)

Publication Number Publication Date
WO2008015563A2 WO2008015563A2 (en) 2008-02-07
WO2008015563A3 true WO2008015563A3 (en) 2008-04-03

Family

ID=38817799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002242 Ceased WO2008015563A2 (en) 2006-08-04 2007-08-03 Salts of rosuvastatin and processes for their preparation

Country Status (2)

Country Link
EP (1) EP2066644A2 (en)
WO (1) WO2008015563A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036286A1 (en) 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
MX2011007478A (en) 2009-01-15 2011-09-15 Sag Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsa Process for the preparation of rosuvastatin salts.
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
HUE029858T2 (en) * 2009-07-24 2017-04-28 Egyt Gyogyszervegyeszeti Gyar Crystalline form i rosuvastatin zinc salt
TR201009397A2 (en) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
HU230737B1 (en) * 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Process for preparation of rosuvastatin salt
HU230987B1 (en) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Process for the preparation of pharmaceutical intermediates with high purity
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof

Also Published As

Publication number Publication date
WO2008015563A2 (en) 2008-02-07
EP2066644A2 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
WO2008015563A3 (en) Salts of rosuvastatin and processes for their preparation
WO2006023627A8 (en) Rapamycin polymorph ii and uses thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
TW200744588A (en) Pharmaceutical composition for external use
PL2054411T3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
IL205071A (en) Azolecarboxamide compound or salt thereof, a pharmaceutical composition comprising the same and uses thereof
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007028135A3 (en) Imidazopyridine compounds
WO2007135529A3 (en) Azabenzimidazolyl compounds as mglur2 potentiators
IL192298A (en) Heterocyclic compounds, pharmaceutical acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof
WO2008051942A3 (en) Farnesoid x receptor agonists
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
WO2004014384A3 (en) Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
IL204520A0 (en) Oxadiazole diaryl compounds, their preparation and pharmaceutical compositions containing them
TW200806282A (en) Solid dosage formulations
WO2007050802A3 (en) Novel opioid antagonists
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007103762A3 (en) Compositions and methods of use of electron transport system inhibitors
EP2644614A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
EP1861358A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804703

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007804703

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU